Blenoxane
information and resources from the National Cancer Institute
bleomycin Bristol-Myers Squibb Jul 31 1973
bleomycin
Sclerosing agent for the treatment of malignant pleural effusion (MPE) and prevention of recurrent pleural effusions.
Bristol-Myers Squibb Feb 20 1996
|
|
|
|
news articles
ABVD Remains Best Treatment for Advanced Hodgkin’s Lymphoma Oct 21, 2005
Cancer Consultants (press release), The standard chemotherapy regimen for these patients has been ABVD: doxorubicin (Adriamycin®), bleomycin (Blenoxane®), Velban® (vinblastine), and ...
|
|
